KRAS and neoplasm: Interestingly, comparing the activity of KRAS G12C inhibitors in immunocompetent versus immunodeficient mice, greater activity is observed in the former scenario, suggesting that the pro-inflammatory tumor microenvironment may sustain therapeutic response, opening up opportunities for studies with combination therapies, including immunotherapy [111,112].